Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S.

Ann Oncol. 2019 Jan 1;30(1):44-56. doi: 10.1093/annonc/mdy495.

2.

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD.

J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16. Erratum in: J Clin Oncol. 2018 Jun 1;36(16):1645.

3.

Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.

Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, Yao H.

JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.

4.

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.

Wang Z, Duan J, Cai S, Han M, Dong H, Zhao J, Zhu B, Wang S, Zhuo M, Sun J, Wang Q, Bai H, Han J, Tian Y, Lu J, Xu T, Zhao X, Wang G, Cao X, Li F, Wang D, Chen Y, Bai Y, Zhao J, Zhao Z, Zhang Y, Xiong L, He J, Gao S, Wang J.

JAMA Oncol. 2019 May 1;5(5):696-702. doi: 10.1001/jamaoncol.2018.7098.

5.

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R.

Mol Cancer Ther. 2017 Nov;16(11):2598-2608. doi: 10.1158/1535-7163.MCT-17-0386. Epub 2017 Aug 23.

6.

The clinical utility of tumor mutational burden in non-small cell lung cancer.

Greillier L, Tomasini P, Barlesi F.

Transl Lung Cancer Res. 2018 Dec;7(6):639-646. doi: 10.21037/tlcr.2018.10.08. Review.

7.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

8.

Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.

Hendriks LE, Rouleau E, Besse B.

Transl Lung Cancer Res. 2018 Dec;7(6):647-660. doi: 10.21037/tlcr.2018.09.22. Review.

9.

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.

Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, Hoyt C, Pardoll DM, Danilova L, Taube JM.

JAMA Oncol. 2019 Jul 18. doi: 10.1001/jamaoncol.2019.1549. [Epub ahead of print]

PMID:
31318407
10.

Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?

Heeke S, Hofman P.

Transl Lung Cancer Res. 2018 Dec;7(6):631-638. doi: 10.21037/tlcr.2018.08.04. Review.

11.

Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.

Kim HS, Cha H, Kim J, Park WY, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.

Eur J Cancer. 2019 Oct;120:65-74. doi: 10.1016/j.ejca.2019.08.001. Epub 2019 Sep 4.

PMID:
31493723
12.

Assessment of tumor mutation burden calculation from gene panel sequencing data.

Xu Z, Dai J, Wang D, Lu H, Dai H, Ye H, Gu J, Chen S, Huang B.

Onco Targets Ther. 2019 May 6;12:3401-3409. doi: 10.2147/OTT.S196638. eCollection 2019.

13.

Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.

Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, Tamragouri K, Rhee K, Mohindra N, Villaflor V, Park W, Lopes G, Giles FJ.

Oncologist. 2019 Jun;24(6):820-828. doi: 10.1634/theoncologist.2018-0433. Epub 2019 Mar 13.

PMID:
30867242
14.

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, Lieber DS, Roels S, White J, Otto GA, Ross JS, Garraway L, Miller VA, Stephens PJ, Frampton GM.

Genome Med. 2017 Apr 19;9(1):34. doi: 10.1186/s13073-017-0424-2.

15.

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.

Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, Sokol ES, Frampton G, Schrock AB, Anhorn R, Reddy P.

Oncologist. 2019 Oct 2. pii: theoncologist.2019-0244. doi: 10.1634/theoncologist.2019-0244. [Epub ahead of print]

PMID:
31578273
16.

Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.

Vilimas T.

Methods Mol Biol. 2020;2055:63-91. doi: 10.1007/978-1-4939-9773-2_3.

PMID:
31502147
17.

Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.

Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, Malapelle U, Group IY.

Biomed Res Int. 2019 Apr 24;2019:9056417. doi: 10.1155/2019/9056417. eCollection 2019. Review.

18.

Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?

Dempke WCM, Fenchel K, Dale SP.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S275-S279. doi: 10.21037/tlcr.2018.04.18.

19.

Optimizing panel-based tumor mutational burden (TMB) measurement.

Budczies J, Allgäuer M, Litchfield K, Rempel E, Christopoulos P, Kazdal D, Endris V, Thomas M, Fröhling S, Peters S, Swanton C, Schirmacher P, Stenzinger A.

Ann Oncol. 2019 Sep 1;30(9):1496-1506. doi: 10.1093/annonc/mdz205.

PMID:
31268125
20.

Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing.

Hatakeyama K, Nagashima T, Urakami K, Ohshima K, Serizawa M, Ohnami S, Shimoda Y, Ohnami S, Maruyama K, Naruoka A, Akiyama Y, Kusuhara M, Mochizuki T, Yamaguchi K.

Biomed Res. 2018;39(3):159-167. doi: 10.2220/biomedres.39.159.

Supplemental Content

Support Center